Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ESTA
ESTA logo

ESTA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
74.000
Open
71.390
VWAP
72.32
Vol
273.94K
Mkt Cap
2.12B
Low
70.768
Amount
19.81M
EV/EBITDA(TTM)
--
Total Shares
29.43M
EV
2.32B
EV/OCF(TTM)
--
P/S(TTM)
9.30
Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.
Show More

Events Timeline

(ET)
2026-05-06
08:10:00
Company Reports Q1 Revenue of $59.9M, Exceeding Expectations
select
2026-05-06
08:10:00
Company Expects Minimally Invasive Business to Exceed $35M in 2026
select
2026-04-30 (ET)
2026-04-30
09:00:00
Establishment Labs Secures $300M Loan Facility
select
2026-04-17 (ET)
2026-04-17
16:00:00
Asana Short Interest Soars to 33%
select
2026-04-07 (ET)
2026-04-07
08:10:00
Establishment Labs Surpasses 5 Million Motiva Devices
select

News

Globenewswire
8.5
05-22Globenewswire
Conexeu Sciences Inc. Goes Public, Pioneering a New Era in Regenerative Medicine
  • IPO Milestone: Conexeu Sciences Inc. successfully debuted on Nasdaq on May 21, 2026, with 25,269,996 shares outstanding and a fully diluted total of 35,238,222 shares, marking a significant advancement in regenerative medicine and enhancing its market competitiveness.
  • Innovative Product Launch: The company unveiled its 3D bioprinted regenerative breast matrix, B.R.E.A.S.T.™, designed to provide a temporary scaffold for patients post-mastectomy, targeting over 100,000 women annually who opt out of reconstruction, thus opening a larger market opportunity.
  • Platform Advantage: Conexeu's CXU™ platform can be applied across multiple tissue regeneration products, streamlining product development processes and targeting multi-billion-dollar markets in wound care, periodontal applications, and facial contouring, indicating vast market potential.
  • Regulatory Strategy: The company plans to submit a 510(k) application in early 2027, transitioning its products from investigational to commercial status, further solidifying its leadership position in the regenerative medicine sector.
Newsfilter
8.5
05-22Newsfilter
Conexeu Sciences Inc. Goes Public, Pioneering a New Era in Regenerative Medicine
  • IPO Milestone: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with 25,269,996 shares outstanding and 35,238,222 on a fully diluted basis, marking a significant advancement in regenerative medicine and expected to enhance its market competitiveness.
  • Innovative Product Launch: The company unveiled B.R.E.A.S.T.™, a 3D-printed regenerative breast matrix designed to provide a temporary scaffold for women post-mastectomy, addressing a market gap faced by over 100,000 women annually, indicating substantial market potential.
  • Platform Technology Advantage: Conexeu's CXU™ platform can be applied across multiple tissue regeneration products, streamlining product development processes and is expected to drive expansion into multi-billion-dollar markets such as wound care, periodontal applications, and facial contouring, enhancing overall business growth potential.
  • Regulatory Outlook: The company plans to submit a 510(k) application in early 2027, marking a transition from preclinical to commercialization; if approved, this will open new revenue streams and bolster investor confidence.
Fool
5.0
05-12Fool
Founder Juan José Chacón Quirós Sells 105,000 Shares Indirectly
  • Indirect Share Sale: Founder and former CEO Juan José Chacón Quirós indirectly sold 105,000 shares through Sariel Group Ltd for approximately $7.92 million, representing 9.74% of his total holdings, indicating his continued confidence in the company's future.
  • Ownership Structure Analysis: Post-transaction, Chacón Quirós retains 45,193 direct shares and 927,504 indirect shares, with direct ownership valued at around $3.37 million, underscoring his significant position within the company remains intact.
  • Historical Trading Comparison: This sale marks the largest single transaction by Chacón Quirós to date, reflecting a constraint on future direct share transactions, which may impact his trading strategy going forward.
  • Future Trading Outlook: With all shares under the December 2025 10b5-1 plan now sold, any future trading will require a new plan or rely on open-market trading windows, potentially increasing uncertainty in the sales cadence.
NASDAQ.COM
5.0
05-12NASDAQ.COM
Founder Sells 105,000 Shares Indirectly
  • Share Sale Overview: Founder and former CEO Juan José Chacón Quirós indirectly sold 105,000 shares of Establishment Labs Holdings Inc. on May 6, 2026, generating approximately $7.92 million at a weighted average price of $75.42 per share, reducing indirect holdings to 927,504 shares while direct holdings remain at 45,193 shares.
  • Financial Performance Highlights: On the same day, the Q1 earnings report revealed U.S. revenue of $19.6 million, reflecting a 13.3% increase from Q4 2025, and the company achieved its third consecutive quarter of positive adjusted EBITDA, indicating strong financial performance and growth potential.
  • Strategic Plan Impact: The share sale was pre-scheduled under a 10b5-1 plan adopted in December 2025, and although it coincided with the earnings release, it does not reflect performance expectations, suggesting the founder maintains an optimistic outlook on the company's future development.
  • Future Outlook: The company raised its full-year guidance and is targeting positive free cash flow in the second half of 2026, with a reconstruction approval application pending, which could provide new momentum for future growth.
Yahoo Finance
9.5
05-07Yahoo Finance
Establishment Labs Reports 45% Revenue Growth in Q1 2026
  • Strong Revenue Growth: Establishment Labs Holdings Inc reported $59.9 million in revenue for Q1 2026, reflecting a 45% year-over-year increase, indicating robust market performance and growth potential.
  • Exceptional U.S. Performance: The U.S. business experienced a remarkable 216% revenue growth, primarily driven by the successful launch of the Motiva platform, showcasing rapid market penetration and increased customer acceptance.
  • Improved Gross Margin: Gross margin improved by 350 basis points to 70.7%, reflecting enhanced operational efficiency and increased sales of higher-margin products, which further strengthens the company's profitability.
  • Raised Full-Year Guidance: The company raised its full-year revenue guidance to $266.5 million to $268.5 million, demonstrating confidence in continued growth despite geopolitical uncertainties and ongoing financial pressures.
seekingalpha
9.5
05-06seekingalpha
Establishment Labs Reports Strong Q1 2026 Earnings with Increased Guidance
  • Significant Revenue Growth: Establishment Labs reported $59.9 million in revenue for Q1 2026, reflecting nearly 45% growth year-over-year, demonstrating strong performance in the U.S. market, particularly achieving quarter-over-quarter growth in a seasonally light quarter, which validates the acceleration of its market launch.
  • Positive Adjusted EBITDA: The company achieved an adjusted EBITDA of $1.2 million in Q1, a substantial turnaround from a loss of $12.1 million in the same quarter last year, marking the third consecutive quarter of positive EBITDA, indicating ongoing improvements in profitability and operational efficiency.
  • Increased Full-Year Guidance: Establishment Labs raised its full-year revenue guidance to $266.5 million to $268.5 million, up from the previous range of $264 million to $266 million, reflecting strong confidence in market demand, particularly as U.S. order counts hit new weekly highs.
  • Positive Cash Flow Outlook: Management expects to achieve cash flow positive status in the second half of 2026 and has successfully refinanced its credit facility, showcasing robust financial management and confidence in future growth prospects.
Wall Street analysts forecast ESTA stock price to rise
8 Analyst Rating
Wall Street analysts forecast ESTA stock price to rise
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
75.00
Averages
82.88
High
90.00
Current: 0.000
sliders
Low
75.00
Averages
82.88
High
90.00
BTIG
Buy
maintain
$88 -> $90
AI Analysis
2026-05-07
Reason
BTIG
Price Target
$88 -> $90
AI Analysis
2026-05-07
maintain
Buy
Reason
BTIG raised the firm's price target on Establishment Labs to $90 from $88 and keeps a Buy rating on the shares. The company's results were driven by continued U.S. Motiva outperformance, with revenue of $19.6M representing 13% sequential growth despite the seasonally softer quarter, and momentum has carried into Q2 with the company setting new weekly order highs, the analyst tells investors in a research note.
Citi
Joanne Wuensch
Neutral
maintain
$65 -> $76
2026-05-06
Reason
Citi
Joanne Wuensch
Price Target
$65 -> $76
2026-05-06
maintain
Neutral
Reason
Citi analyst Joanne Wuensch raised the firm's price target on Establishment Labs to $76 from $65 and keeps a Neutral rating on the shares. The firm says this was "a straightforward quarter," with a modest guidance raise as management ramps the pipeline. It seems that the U.S. Motiva launch and global Preserve launch are progressing in line or exceeding expectations, with the relatively benign guidance raise likely a reflection of conservatism, Citi adds. Still, with several launches still nascent and an uncertain global economy, the firm stays on the sidelines.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ESTA
Unlock Now

Valuation Metrics

The current forward P/E ratio for Establishment Labs Holdings Inc (ESTA.O) is 0.00, compared to its 5-year average forward P/E of -31.31. For a more detailed relative valuation and DCF analysis to assess Establishment Labs Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-31.31
Current PE
0.00
Overvalued PE
-13.34
Undervalued PE
-49.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-86.62
Current EV/EBITDA
-72.06
Overvalued EV/EBITDA
40.93
Undervalued EV/EBITDA
-214.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
7.52
Current PS
6.11
Overvalued PS
9.98
Undervalued PS
5.06

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stocks to pick right now for day trading
Intellectia · 820 candidates
Region: USPrice: >= $5.00Volume: >= 0Rsi Category: moderatePrice Change Pct: >= $0.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA5, PriceAboveMA20, PriceCrossAboveMA5, PriceCrossAboveMA20Min5 Price Change Pct: >= $0.00Intraday Amplitude: >= 0
Ticker
Name
Market Cap$
top bottom
ERNA logo
ERNA
Ernexa Therapeutics Inc
4.65M
SIM logo
SIM
Grupo Simec SAB de CV
4.30B
STRC logo
STRC
Strategy Inc
65.56B
BRID logo
BRID
Bridgford Foods Corp
67.62M
NVAX logo
NVAX
Novavax Inc
1.33B
SLP logo
SLP
Simulations Plus Inc
317.43M
Daytrading Signale andern
Intellectia · 28 candidates
Price: $5.00 - $100.00Relative Vol: >= 1.80Moving Average Relationship: PriceAboveMA20Three Min Rate Of Change: >= 0.7%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ONDS logo
ONDS
Ondas Inc
4.53B
VG logo
VG
Venture Global Inc
27.96B
SOUN logo
SOUN
SoundHound AI Inc
3.63B
VIAV logo
VIAV
Viavi Solutions Inc
8.18B
NTLA logo
NTLA
Intellia Therapeutics Inc
1.82B
LION logo
LION
Lionsgate Studios Corp
2.61B
create a small cap screener
Intellectia · 1387 candidates
Market Cap Category: small
Ticker
Name
Market Cap$
top bottom
SGRY logo
SGRY
Surgery Partners Inc
2.00B
QDEL logo
QDEL
QuidelOrtho Corp
2.00B
NESR logo
NESR
National Energy Services Reunited Corp
2.00B
DXPE logo
DXPE
DXP Enterprises Inc
2.00B
SKWD logo
SKWD
Skyward Specialty Insurance Group Inc
2.00B
NTCT logo
NTCT
Netscout Systems Inc
2.00B
low cap stocks with a bullish cross
Intellectia · 1029 candidates
Market Cap Category: small, micro, nanoMoving Average Relationship: PriceCrossAboveMA5
Ticker
Name
Market Cap$
top bottom
NTCT logo
NTCT
Netscout Systems Inc
2.00B
NESR logo
NESR
National Energy Services Reunited Corp
2.00B
FMC logo
FMC
FMC Corp
1.99B
VECO logo
VECO
Veeco Instruments Inc
1.99B
CMPR logo
CMPR
Cimpress PLC
1.98B
STC logo
STC
Stewart Information Services Corp
1.98B
what about health tech stocks and robots?
Intellectia · 18 candidates
Market Cap: 50.00M - 50.00BWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ROK logo
ROK
Rockwell Automation Inc
47.26B
SYM logo
SYM
Symbotic Inc
36.98B
TER logo
TER
Teradyne Inc
36.32B
VEEV logo
VEEV
Veeva Systems Inc
36.12B
ZBRA logo
ZBRA
Zebra Technologies Corp
12.31B
DOCS logo
DOCS
Doximity Inc
7.50B

Whales Holding ESTA

S
Summit Partners Public Asset Management, LLC
Holding
ESTA
+31.09%
3M Return
N
Nantahala Capital Management, LLC
Holding
ESTA
+8.27%
3M Return
Q
Qatar Holding LLC
Holding
ESTA
+8.09%
3M Return
D
Discovery Capital Management, LLC
Holding
ESTA
+7.20%
3M Return
G
Granite Investment Partners, LLC
Holding
ESTA
+6.80%
3M Return
A
Affinity Asset Advisors, LLC
Holding
ESTA
+5.67%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Establishment Labs Holdings Inc (ESTA) stock price today?

The current price of ESTA is 72.19 USD — it has increased 1.35

What is Establishment Labs Holdings Inc (ESTA)'s business?

Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.

What is the price predicton of ESTA Stock?

Wall Street analysts forecast ESTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESTA is82.88 USD with a low forecast of 75.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Establishment Labs Holdings Inc (ESTA)'s revenue for the last quarter?

Establishment Labs Holdings Inc revenue for the last quarter amounts to 59.88M USD, increased 44.71

What is Establishment Labs Holdings Inc (ESTA)'s earnings per share (EPS) for the last quarter?

Establishment Labs Holdings Inc. EPS for the last quarter amounts to -0.45 USD, decreased -35.71

How many employees does Establishment Labs Holdings Inc (ESTA). have?

Establishment Labs Holdings Inc (ESTA) has 1004 emplpoyees as of May 26 2026.

What is Establishment Labs Holdings Inc (ESTA) market cap?

Today ESTA has the market capitalization of 2.12B USD.